Recently updated guidelines have provided revised recommendations, based on the
GRADE criteria, for the diagnosis and pharmacological and non-pharmacological …

The magnitude of treatment effect can be assessed by a number of methods. One method of
collectively analysing data is that used by the Cochrane Collaboration. Their systematic …

Despite multiple clinical trials, there is no strong, definitive evidence in favor of any agent to
treat IPF. On the other hand, the placebo arms of these large trials have provided us with …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with
poor prognosis and a high economic burden for individuals and healthcare resources …

Randomised controlled clinical trials are fundamental in medicine to develop new effective
drugs and new therapeutic regimens and are the strength of evidence-based medicine …

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown
cause. Approximately 5,000 people are diagnosed with IPF in the UK every year. People …

Background Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with
high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies …

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disorder of unknown etiology.
The consensus statement released by the American Thoracic Society and European …

Idiopathic pulmonary fibrosis (IPF) is the most prevalent of the idiopathic interstitial
pneumonias and its incidence seems to be increasing [1–4]. IPF is generally considered to …